Trials / Completed
CompletedNCT01232543
Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis
An Open-Label Evaluation of the Adrenal Suppression Potential of Product 0405 in the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 114 (actual)
- Sponsor
- Fougera Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 3 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the trial is to assess Adrenal Suppression potential when pediatric subjects are administered Product 0405 for the treatment of Atopic Dermatitis
Detailed description
Treatment medication will be administered topically, twice a day for 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Product 0405 | Product 0405 will be administered topically, twice daily for 28 days. |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-08-01
- Completion
- 2011-11-01
- First posted
- 2010-11-02
- Last updated
- 2012-04-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01232543. Inclusion in this directory is not an endorsement.